Jeffrey E. Gershenwald

Roswell Park Comprehensive Cancer Center — United States

Medicine · Health Sciences

101h-index58.8kcitations698works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(326), Melanoma and MAPK Pathways(188), Cancer Immunotherapy and Biomarkers(135), CAR-T cell therapy research(115), Immunotherapy and Immune Responses(103)

Publications691 total

Editor’s Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Cancer Discovery·2025Open Access
Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Tables 1 and 6-8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S7 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Table 4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Supplementary Table 3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
2025Open Access
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
Annals of Oncology·2025
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma
OncoImmunology·2025· 1 citedOpen Access
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma
Journal of Clinical Oncology·2025· 7 citedOpen Access
A Refresher on the Key Terminologies and Principles of the American Joint Committee on Cancer (AJCC) Staging System
Journal of the National Comprehensive Cancer Network·2025
Corrigendum to “Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features” [Modern Pathology 33 (2020) 496–513]
Modern Pathology·2025
Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB/C melanoma.
Journal of Clinical Oncology·2025· 4 cited
page 1 of 35Next →

Frequent Co-authors

Merrick I. Ross(23), Michael A. Davies(20), Alexander J. Lazar(15), Jennifer A. Wargo(15), Charles M. Balch(11), Kelly M. McMasters(11), Isabella C. Glitza(11), Scott E. Woodman(11), Rodabe N. Amaria(11), Jeffrey E. Lee(11), John F. Thompson(10), Sapna P. Patel(10), Michael T. Tetzlaff(10), Víctor G. Prieto(10), John M. Kirkwood(9), Hussein A. Tawbi(9), Daniel G. Coit(8), Vancheswaran Gopalakrishnan(8), Alexandre Reuben(8), Lauren E. Haydu(8)